Method for the purification of G-CSF

Patent metadata

Field	Value
Publication number	US-9815879-B2
Application number	US-99567906-A
Country	US
Kind code	B2
Filing date	Jul 14, 2006
Priority date	Jul 15, 2005
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

The present invention relates to a method for obtaining recombinant granulocyte-colony stimulating factor (G-CSF), comprising at least one cation exchange chromatography and at least one hydrophobic interaction chromatography, wherein said two chromatographic steps are immediately consecutive in optional order. In particular, the present invention relates to a method for purifying G-CSF from a mixture of G-CSF and other proteins, comprising two cation exchange chromatography steps which are conducted before and after a hydrophobic interaction chromatography, respectively.

First claim

The invention claimed is:

1. A method of purifying granulocyte-colony stimulating factor (G-CSF), said method comprising:
(a) subjecting a refolded G-CSF composition to cation exchange chromatography to achieve a purity of at least about 80%;
(b) subjecting the cation-exchange-chromatography-purified G-CSF composition of step (a) to hydrophobic interaction chromatography to achieve a purity of at least about 96%;
(c) subjecting the hydrophobic-interaction-chromatography-purified G-CSF composition of step (b) to cation exchange chromatography to achieve a purity of at least about 99%; and
(d) subjecting the cation-exchange-chromatography-purified G-CSF composition of step (c) to a tangential flow filtration step;
wherein said G-CSF was expressed in E. coli before being refolded; and
wherein no affinity chromatographic steps are included in the purification method.

2. The method of claim 1 , wherein said cation-exchange-chromatography step (a) comprises eluting G-CSF from a cation-exchange-chromatography column using a buffer having a NaCl concentration of at least 200 mM NaCl.

3. The method of claim 1 , wherein said hydrophobic-interaction-chromatography step (b) comprises Phenyl Sepharose HP as a chromatography matrix.

4. The method of claim 2 , wherein said hydrophobic-interaction-chromatography step (b) comprises using Phenyl Sepharose HP as a chromatography matrix.

5. The method of claim 1 , wherein the cation exchange matrix used in said cation-exchange-chromatography step (a) comprises carboxymethyl groups.

6. The method of claim 1 , wherein the cation exchange matrix used in said cation-exchange-chromatography step (a) comprises sulfopropvl groups.

7. The method of claim 1 , wherein the same type of cation exchange matrix is used for the cation exchange chromatography steps in step (a) and step (c).

8. The method of claim 7 , wherein the cation exchange matrix comprises sulfopropyl groups.

9. The method of claim 1 , wherein the hydrophobic interaction matrix comprises hydrophobic ligands selected from butyl, phenyl, and octyl groups.

10. The method of claim 9 , wherein the hydrophobic interaction matrix comprises phenyl hydrophobic ligands.

11. A method of purifying granulocyte-colony stimulating factor (G-CSF) said method comprising:
(a) subjecting a refolded G-CSF composition to cation exchange chromatography using a matrix comprising sulfopropyl groups to achieve a purity of at least about 80%;
(b) subjecting the cation-exchange-chromatography-purified G-CSF composition of step (a) to hydrophobic interaction chromatography using a matrix comprising a hydrophobic ligand comprising phenyl groups to achieve a purity of at least about 96%;
(c) subjecting the hydrophobic-interaction-chromatography-purified G-CSF composition of step (b) to cation exchange chromatography using a matrix comprising sulfopropyl groups to achieve a purity of at least about 99%; and
(d) subjecting the cation-exchange-chromatography-purified G-CSF composition of step (c) to a tangential flow filtration step;
wherein said G-CSF was expressed in E. coli before being refolded; and
wherein no affinity chromatographic steps are included in the purification method.

12. A method of purifying granulocyte-colony stimulating factor (G-CSF), said method comprising:
(a) subjecting a refolded G-CSF composition to cation exchange chromatography using a matrix comprising sulfopropyl or carboxylmethyl groups to achieve a purity of at least about 80%;
(b) subjecting the cation-exchange-chromatography-purified G-CSF composition of step (a) to hydrophobic interaction chromatography using a matrix comprising hydrophobic ligands selected from butyl, phenyl or octyl groups to achieve a purity of at least about 96%;
(c) subjecting the hydrophobic-interaction-chromatography-purified G-CSF composition of step (b) to cation exchange chromatography using a matrix comprising sulfopropyl or carboxymethyl groups to achieve a purity of at least about 99%; and
(d) subjecting the cation-exchange-chromatography-purified G-CSF composition of step (c) to a tangential flow filtration step;
wherein said G-CSF was expressed in E. coli before being refolded; and
wherein no affinity chromatographic steps are included in the purification method.

13. The method of claim 12 , wherein in step (a), the cation exchange chromatography matrix comprises carboxylmethyl groups.

14. The method of claim 12 , wherein in step (a), the cation exchange chromatography matrix comprises sulfopropyl groups.

15. The method of claim 12 , wherein in step (b), the hydrophobic ligands are phenyl groups.

Assignees

• Dietrich Arndt
• Janowski Bernhard
• Schäffner Jörg
• Blaschke Ulrich Kurt
• Sandoz Ag

Inventors

• Dietrich Arndt
• Janowski Bernhard
• Schäffner Jörg
• Blaschke Ulrich Kurt

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title